AbbVie’s Humira (adalimumab) and Merck, Sharp, and Dohme’s (MSD) Remicade (infliximab) are mega-blockbusters – but Humira is nearing the end of its patent life in the EU, and Remicade is no ...

Adalimumab-Adbm injection ... Ezetimibe; Simvastin tablet: Merck has discontinued its cholesterol-lowering combination therapy. These products were expected to be unavailable starting in January.

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...